Your session is about to expire
← Back to Search
Avutometinib for Solid Tumors
Study Summary
This trial studies avutometinib to see if it's safe & effective as a cancer treatment for children & young adults with advanced/recurring tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there a possibility that I could be enrolled in this experiment?
"For enrolment into the current clinical trial, candidates must have a central nervous system tumor and should be between 3 to 30 years of age. 24 participants are planned for this research program."
Does Dose Level -1 pose a safety hazard to participants?
"There is limited evidence that supports the safety and efficacy of Dose Level -1, so it was rated a 1 by our Power team."
How many participants is this trial aiming to recruit?
"Affirmative. According to clinicaltrials.gov, the trial was launched on October 20th 2023 and is still actively recruiting participants. 24 individuals must be gathered from two various sites for this medical study."
Are participants younger than 45 years of age able to be enrolled in this study?
"This clinical trial is recruiting patients aged 3 to 30. There are 649 trials catered towards minors and 3228 for elderly individuals."
Are there current opportunities for medical participants to join this experiment?
"Affirmative. Per the information on clinicaltrials.gov, it is apparent that this medical experiment has opened its recruitment period. It was first published on October 20th 2023 and most recently revised four days later, with a target of 24 participants to be sourced from two separate locations."
Share this study with friends
Copy Link
Messenger